This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

SIMPLICITY

NINLARO + Rd offers the convenience of all-oral administration2

The usual recommended starting dose of oral NINLARO is one 4 mg capsule taken once a week with lenalidomide and dexamethasone at standard dosing2

  • Should be taken at least 1 hour before or at least 2 hours after food2
  • Should be swallowed whole with a glass of water2
  • Antiviral prophylaxis should be considered to reduce the risk of herpes zoster reactivation2
TOURMALINE‑MM1 study design

*The recommended starting dose of dexamethasone is 40 mg - each tablet contains 2 mg dexamethasone

Treatment with NINLARO in combination with Rd for longer than 24 cycles should be based on an individual benefit risk assessment1

If a dose of NINLARO is delayed or missed, the dose should be taken only if the next scheduled dose is ≥72 hours away2

NINLARO should be stored in the original packaging and the capsules should be removed just prior to dosing2

The recommended starting dose of oral NINLARO is 3 mg for patients with moderate or severe hepatic impairment, severe renal impairment or end-stage renal disease requiring dialysis2

View Ninlaro prescribing information

Adding oral NINLARO to Rd requires no additional planned hospital visits2

Minimum number of planned hospital visits required for administration/collection of multiple myeloma treatments over 18 cycles2,5-7†

Rd

18 visits

    NINLARO  + Rd

    18 visits

      Carfilzomib  + Rd

      96 visits

        Patients are treated until progression or unacceptable toxicity. Calculation excludes visits for monitoring. Standard carfilzomib regimen is 18 cycles; number of administrations of carfilzomib per cycle: cycle 1-12 = 6 doses (2 consecutive doses each week for 3 weeks), cycle 13-18 = 4 doses (2 consecutive doses during 1st and 3rd week). Treatment with carfilzomib + Rd for longer than 18 cycles should be based on an individual benefit risk assessment, as the data on the tolerability and toxicity of carfilzomib beyond 18 cycles are limited7